Zobrazeno 1 - 10
of 1 276
pro vyhledávání: '"Stass, H"'
Autor:
Stass H; Bayer AG, Clinical PK CV, Research & Development, Pharmaceuticals, Building 0431, Wuppertal, 42096, Germany. heino.stass@bayer.com., Ince I; Research & Development, Pharmaceuticals, Bayer AG, Building B106, Leverkusen, 51368, Germany., Grossmann U; Clinical Development & Operations, Bayer AG, Building P300, Müllerstrasse 178, Berlin, 13353, Germany., Weimann B; Chrestos Concept GmbH & Co. KG, Essen, Germany., Willmann S; Bayer AG, Clinical PK CV, Research & Development, Pharmaceuticals, Building 0431, Wuppertal, 42096, Germany.
Publikováno v:
The AAPS journal [AAPS J] 2022 Aug 24; Vol. 24 (5), pp. 92. Date of Electronic Publication: 2022 Aug 24.
Autor:
Ince I; Clinical Pharmacometrics, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany., Prins K; qPharmetra, LLC, Nijmegen, The Netherlands., Willmann S; Clinical Pharmacometrics, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany., Sutter G; Clinical Pharmacometrics, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany., Hanze E; qPharmetra, LLC, Nijmegen, The Netherlands., Sadre-Marandi F; qPharmetra, LLC, Nijmegen, The Netherlands., Stass H; Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Garmann D; Clinical Pharmacometrics, Research & Development, Pharmaceuticals, Bayer AG, Leverkusen, Germany.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2022 Oct; Vol. 62 (10), pp. 1273-1284. Date of Electronic Publication: 2022 May 10.
Publikováno v:
Chemical research in toxicology [Chem Res Toxicol] 2023 May 15; Vol. 36 (5), pp. 790-791. Date of Electronic Publication: 2023 Apr 18.
Publikováno v:
In Journal of Thrombosis and Haemostasis February 2008 6(2):277-283
Autor:
Schulz SI; Bayer AG, 42096 Wuppertal, Germany., Lang D; Bayer AG, 42096 Wuppertal, Germany., Schmuck G; Bayer AG, 42096 Wuppertal, Germany., Gerisch M; Bayer AG, 42096 Wuppertal, Germany., Bairlein M; Bayer AG, 42096 Wuppertal, Germany., Fricke R; Bayer AG, 42096 Wuppertal, Germany., Stass H; Bayer AG, 42096 Wuppertal, Germany.
Publikováno v:
Current drug metabolism [Curr Drug Metab] 2023; Vol. 24 (8), pp. 599-610.
Autor:
Lang D; Drug Metabolism and Pharmacokinetics, Bayer AG, 42096 Wuppertal, Germany., Schulz SI; Bayer AG, 42096 Wuppertal, Germany., Piel I; Bayer AG, 42096 Wuppertal, Germany., Tshitenge DT; Bayer AG, 42096 Wuppertal, Germany., Stass H; Bayer AG, 42096 Wuppertal, Germany.
Publikováno v:
Chemical research in toxicology [Chem Res Toxicol] 2022 Nov 21; Vol. 35 (11), pp. 2037-2048. Date of Electronic Publication: 2022 Oct 09.
Autor:
Stass H; Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany. Electronic address: heino.stass@bayer.com., Just S; Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany., Weimann B; Chrestos Concept GmbH & Co. KG, 45131 Essen, Germany., Ince I; Bayer AG, 51368 Leverkusen, Germany., Willmann S; Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany., Feleder E; FP Clinical Pharma, Buenos Aires, Argentina., Freitas C; Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany., Yerino G; FP Clinical Pharma, Buenos Aires, Argentina., Münster U; Bayer AG, Research & Development - Pharmaceuticals, Clinical PK CV, Building 0431 - 403, 42096 Wuppertal, Germany.
Publikováno v:
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2021 Nov 01; Vol. 166, pp. 105940. Date of Electronic Publication: 2021 Jul 12.
Autor:
Gillon JY; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Dennison J; Hammersmith Medicines Research Ltd, London, UK., van den Berg F; Hammersmith Medicines Research Ltd, London, UK.; Invicro, Burlington Danes Building, Imperial College London, Hammersmith Hospital, London, UK., Delhomme S; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Dequatre Cheeseman K; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Peña Rossi C; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Strub Wourgaft N; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Specht S; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Pedrique B; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Monnot F; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Skrabs S; Bayer AG, Wuppertal, Germany., Rodriguez ML; Bayer AG, Wuppertal, Germany., Stass H; Bayer AG, Wuppertal, Germany.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2021 Oct; Vol. 87 (10), pp. 3949-3960. Date of Electronic Publication: 2021 Mar 31.
Autor:
Stass, H.1 heino.stass@bayerhealthcare.com
Publikováno v:
Haemophilia. Sep2006 Supplement, Vol. 12, p50-55. 6p. 2 Charts, 4 Graphs.
Autor:
Stass, H., Kubitza, D.
Publikováno v:
Clinical Infectious Diseases; 3/15/2001 Supplement 1, Vol. 32, pS47, 4p